Literature DB >> 22966025

Incidence of chronic bilirubin encephalopathy in Canada, 2007-2008.

Michael Sgro1, Douglas M Campbell, Sharmilaa Kandasamy, Vibhuti Shah.   

Abstract

BACKGROUND AND OBJECTIVES: Despite the implementation of screening guidelines to identify infants at risk for hyperbilirubinemia, chronic bilirubin encephalopathy (CBE) continues to be reported worldwide in otherwise healthy infants. The incidence of CBE in Canada is unknown. The objectives of this study were to establish the incidence of CBE in Canada and identify epidemiological and medical risk factors associated with its occurrence.
METHODS: Data on infants were collected prospectively through the Canadian Pediatric Surveillance Program. Infants born between January 1, 2007 and December 31, 2008 were included if they either had symptoms of CBE and a history of hyperbilirubinemia, or if they presented in the newborn period with severe hyperbilirubinemia and an abnormal MRI finding as per the reporting physician.
RESULTS: During the study period, 20 cases were identified; follow-up data were available for 14 of these. The causes for the hyperbilirubinemia included glucose-6-phosphate dehydrogenase deficiency (n = 5), sepsis (n = 2), ABO incompatibility and other red blood cell antibodies (n = 7). Fifteen infants had abnormal brain MRI findings during the neonatal period. At follow-up, 5 infants developed classic choreoathetoid cerebral palsy, 6 had spectrum of neurologic dysfunction and developmental delay (as described by the reporting physician), and 3 were healthy.
CONCLUSIONS: CBE continues to occur in Canada at an incidence that appears to be higher than previously reported.

Entities:  

Mesh:

Year:  2012        PMID: 22966025     DOI: 10.1542/peds.2012-0253

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  20 in total

Review 1.  Managing the jaundiced newborn: a persistent challenge.

Authors:  M Jeffrey Maisels
Journal:  CMAJ       Date:  2014-11-10       Impact factor: 8.262

2.  Predictive value of cord blood bilirubin for hyperbilirubinemia in neonates at risk for maternal-fetal blood group incompatibility and hemolytic disease of the newborn.

Authors:  K Calkins; D Roy; L Molchan; L Bradley; T Grogan; D Elashoff; V Walker
Journal:  J Neonatal Perinatal Med       Date:  2015

Review 3.  Bilirubin nomograms for identification of neonatal hyperbilirubinemia in healthy term and late-preterm infants: a systematic review and meta-analysis.

Authors:  Zhang-Bin Yu; Shu-Ping Han; Chao Chen
Journal:  World J Pediatr       Date:  2014-08-15       Impact factor: 2.764

Review 4.  Glucose-6-Phosphate Dehydrogenase Deficiency and the Need for a Novel Treatment to Prevent Kernicterus.

Authors:  Anna D Cunningham; Sunhee Hwang; Daria Mochly-Rosen
Journal:  Clin Perinatol       Date:  2016-02-28       Impact factor: 3.430

5.  A decision-making tool for exchange transfusions in infants with severe hyperbilirubinemia in resource-limited settings.

Authors:  B O Olusanya; I F Iskander; T M Slusher; R P Wennberg
Journal:  J Perinatol       Date:  2016-03-03       Impact factor: 2.521

6.  Cost savings with transcutaneous screening versus total serum bilirubin measurement for newborn jaundice in hospital and community settings: a cost-minimization analysis.

Authors:  Stephanie McClean; Krista Baerg; Julie Smith-Fehr; Michael Szafron
Journal:  CMAJ Open       Date:  2018-07-27

7.  Clinical Decision Support for Hyperbilirubinemia Risk Assessment in the Electronic Health Record.

Authors:  John D Petersen; Margaret Lozovatsky; Daniela Markovic; Ray Duncan; Simon Zheng; Arash Shamsian; Sonya Kagele; Mindy K Ross
Journal:  Acad Pediatr       Date:  2020-02-10       Impact factor: 3.107

8.  Population-based study of early-onset neonatal sepsis in Canada.

Authors:  Michael Sgro; Anna Kobylianskii; Mark H Yudin; Dat Tran; Julia Diamandakos; Jonathan Sgro; Douglas M Campbell
Journal:  Paediatr Child Health       Date:  2018-04-24       Impact factor: 2.253

Review 9.  Review of bilirubin neurotoxicity I: molecular biology and neuropathology of disease.

Authors:  Sean M Riordan; Steven M Shapiro
Journal:  Pediatr Res       Date:  2019-10-10       Impact factor: 3.756

Review 10.  Review of bilirubin neurotoxicity II: preventing and treating acute bilirubin encephalopathy and kernicterus spectrum disorders.

Authors:  Steven M Shapiro; Sean M Riordan
Journal:  Pediatr Res       Date:  2019-10-03       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.